Tue, 20 Nov 2018 12:00:00 EST Improving Islet Transplantation Outcomes With Gastrin Condition: Diabetes Mellitus, Type 1 Interventions: Biological: Allogenic Human Islet Cells; Drug: Gastrin 17 Sponsors: City of Hope Medical Center; University of California, Los Angeles Not yet recruiting
Tue, 20 Nov 2018 12:00:00 EST Management of Glycemia Following a Pizza Meal Condition: Diabetes Mellitus, Type 1 Interventions: Other: the patients ate a pizza that fermented for 8 hours; Other: the patients ate a pizza that fermented for 24 hours Sponsors: University of Campania "Luigi Vanvitelli"; Federico II University Completed
Tue, 20 Nov 2018 12:00:00 EST Medication Adherence Clinical Decision Support Conditions: Hyperlipidemias; Hypertension; Diabetes; Medication Nonadherence Interventions: Other: Adherence-enhanced clinical decision support; Behavioral: ReachOut Adherence intervention Sponsors: HealthPartners Institute; National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting
Mon, 19 Nov 2018 12:00:00 EST Achieving the Quadruple Aim by Reducing Burnout Condition: Burnout, Professional Intervention: Behavioral: Compassion Curriculum Sponsor: Providence Health & Services Completed
Mon, 19 Nov 2018 12:00:00 EST An Investigational Study of Experimental Medication Supaglutide Injection Given With the Placebo in Healthy Participants Condition: Diabetes Mellitus, Type 2 Interventions: Drug: Supaglutide injection; Drug: Placebo Sponsors: Shanghai Innogen Pharmaceutical Technology Co.,Ltd; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; Tigermed Consulting Co., Ltd; Mosim Co., Ltd.; Linking Truth Technology Co., Ltd.; Medidata Solutions Not yet recruiting
Mon, 19 Nov 2018 12:00:00 EST Effects of Non-alcoholic Beer in Patients With Type 2 Diabetes Condition: Diabetes Mellitus, Type 2 Interventions: Dietary Supplement: Water; Dietary Supplement: Non-alcoholic beer Sponsors: Universidade do Porto; CINTESIS - Centre for Health Technology and Services Research; NOVA Medical School Recruiting
Mon, 19 Nov 2018 12:00:00 EST PDD in Type 2 Diabetes w/wo Diastolic Dysfunction Conditions: Diabetes Mellitus, Type 2; Diastolic Dysfunction Interventions: Drug: Nesiritide Injection; Drug: LCZ 696; Drug: Placebos Sponsor: Mayo Clinic Recruiting
Mon, 19 Nov 2018 12:00:00 EST
FDA (Food and Drug Administration) press releases. FDA makes sure of the safety of all medicines which can be injected, breathed in, rubbed in and swallowed, in the United States of America.
Tue, 20 Nov 2018 11:30:00 -0500 FDA approves first treatment specifically for patients with rare and life-threatening type of immune disease The FDA approved Gamifant (emapalumab-lzsg) for the treatment of pediatric (newborn and above) and adult patients with primary hemophagocytic lymphohistiocytosis (HLH) who have refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. This FDA approval is the first for a drug specifically for HLH.
Mon, 19 Nov 2018 12:54:00 -0500 FDA approves new drug to treat travelers’ diarrhea FDA approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers’ diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.
Fri, 16 Nov 2018 11:11:00 -0500 FDA approves first-line treatment for peripheral T-cell lymphoma under new review pilot The FDA expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL). This is the first FDA approval for treatment of newly diagnosed PTCL, and the agency used a new review program to complete the approval more quickly.
